ClinicalTrials.gg
RecruitingNCT06081686Updated Nov 13, 2026

Study of [177Lu] Lu-XT033 Injection in Patients With Metastatic Prostate Cancer

A Phase 1/2 interventional study of Phase I:[177Lu]Lu-XT033 Injection and Phase II:[177Lu]Lu-XT033 Injection in Prostate Cancer, sponsored by Sinotau Pharmaceutical Group. Recruiting at 2 sites in China. Open to male participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Sinotau Pharmaceutical Group · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.
Updated Nov 13, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing Lutetium-177 in Prostatic Neoplasms — 8 open to participants now, 9 under way, none of them phase 3. Lutetium-177 · Prostatic Neoplasms.

Planned enrollment
6th of 14
32 · median 31
Started
2023
with 2 others
Phase 1/2
4 of 14
3 open now
Registered
5th of 14
by date
Lead sponsor
1 of 14
Sinotau Pharmaceutical Group

Among the 14 studies testing Lutetium-177 in Prostatic Neoplasms, this one is the 6th largest by planned enrollment, is one of 3 that started in 2023, is one of 4 in phase 1/2, and was the 5th registered.

Prostatic Neoplasms

7,052 studies on the registry are indexed under Prostatic Neoplasms; 1,583 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

8 of the 14 studies testing Lutetium-177 in Prostatic Neoplasms are open now, in 9 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About Lutetium-177

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,231 Prostatic Neoplasms studies recruiting now, 930 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 80 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing Lutetium-177 in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This was a multicenter, open-label, phase I/II study to evaluate the safety and tolerability, radiation dosimetry and pharmacokinetic characteristics, and efficacy of [177Lu] Lu-XT033 injection in patients with metastatic prostate cancer, including a phase I study and a phase II extension study.

Read the detailed description

The study for each participant consisted of a Screening period, a Treatment period and a Follow-up period.

In phase I,Six subjects were enrolled in the 1.11 Gbq (30 mCi) group of [177Lu] Lu-XT033 Injection. The last subject in this group completed the 4-week observation period after the first dose, With the consent of the Safety Monitoring Committee (SRC), 6 subjects were enrolled in the 1.85 Gbq (50 mCi) group. Both groups used 8 ± 1 weeks as the dosing interval for a total of 4 doses.In phase II,Subjects who met the inclusion and exclusion criteria were treated with [177Lu] Lu-XT033 injection at the recommended phase II dose(RP2D).After Cycle 4 treatment and prior to Cycle 5 treatment, the investigator assessed the following criteria to determine whether:

The patient showed evidence of response (i.e. radiological, PSA, clinical benefit)

The patient had signs of residual disease on CT with contrast/MRI or bone scan

The patient had shown good tolerance to the [177Lu] Lu-XT033 Injection

If the patient met all of the criteria above and agreed to continue with additional treatment of [177Lu] Lu-XT033, the Investigator could administer 2 additional cycles. A maximum of 6 cycles of [177Lu] Lu-XT033 as allowed.

All subjects continued to undergo safety, tolerability, and efficacy assessments until the study-specified visit occurred or the subject was lost to follow-up or death whichever came first.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Prostate Cancer
  • [177Lu]Lu-XT033 Injection
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients must have the ability to understand and sign an approved form (ICF).
  2. Patients must be >= 18 and \<=80 years of age.
  3. (ECOG) performance status of 0 or 1.
  4. Patients must have a >6 months.
  5. Patients must have histological, pathological, and/or cytological confirmation of prostate cancer.
  6. Patients must be 68Ga-PSMA-11 Positron Emission Tomography (PET)/Computed Tomography (CT) scan positive。
  7. Patients must have a castrate level of serum/plasma testosterone (\<50 ng/dL or \<1.7 nmol/L).
  8. Patients must have received at least one NAAD (such as enzalutamide and/or abiraterone); Patients must have been previously treated with at least 1, but no more than 2 previous taxane regimens.
  9. Patients must have progressive mCRPC.
  10. Patients must have adequate organ function。
  11. Subjects of voluntarily use an effective method of , such as condoms, oral or injectable contraceptives, Intra-uterine device(IUD),etc., during treatment and within 6 months of the last use of the trial drug.

Exclusion criteria

Exclusion Criteria:

  1. Previous treatment with any of the following within 6 months of enrollment: Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223, hemi-body irradiation. Previous PSMA-targeted radioligand therapy is not allowed.
  2. Known other .
  3. Any systemic anti-cancer therapy (e.g. chemotherapy, immunotherapy or biological therapy within 28 days prior to day of enrollment.
  4. Known to the components of the study therapy or its analogs.
  5. A superscan as seen in the baseline bone scan.
  6. Patients with a history of Central Nervous System (CNS) .
  7. Uncontrolled, intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, cardiac arrhythmia, or other severe complications.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Phase I:[177Lu]Lu-XT033 Injection

    During dose verification phase,Patients received \[177Lu\]Lu-XT033 Injection 1.11Gbq(30mCi)/1.85Gbq(50mCi)intravenously every 8 weeks (+/- 1 week) for a maximum of 6 cycles.

    Drug: Phase I:[177Lu]Lu-XT033 Injection

  • Experimental
    Phase II:[177Lu]Lu-XT033 Injection

    During dose expansion phase,patients received \[177Lu\]Lu-XT033 Injection at R2PD based on phase I.

    Drug: Phase II:[177Lu]Lu-XT033 Injection

Interventions

  • Six subjects were enrolled in the 1.11 Gbq (30 mCi) group of \[177Lu\] Lu-XT033 Injection. The last subject in this group completed the 4-week observation period after the first dose, With the consent of the Safety Monitoring Committee (SRC), 6 subjects were enrolled in the 1.85 Gbq (50 mCi) group. Both groups used 8 ± 1 weeks as the dosing interval .

  • Patients received \[177Lu\]Lu-XT033 Injection every 8 weeks (+/- 1 week) for a maximum of 6 cycles.

06

What researchers measure

Primary outcomes

  1. For phase I:Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability])of [177Lu]Lu-XT033 on dose 1.11Gbq and 1.85Gbq

    To evaluate the safety and tolerability of \[177Lu\]Lu-XT033 Injection assessed from the number and incidence of patients with adverse events using CTCAE v5.0 and physical examination, electrocardiogram and laboratory abnormality, etc

    Time frame: Through study completion, assessed up to 2 years.

  2. For phase I:Whole body and organ uptake of [177Lu]Lu-XT033 Injection

    Quantitate the absorbed radiation doses (expressed as Gy/MBq) of administered \[177Lu\]Lu-XT033 to kidneys, liver, lungs, spleen, bone/red marrow and salivary glands.

    Time frame: From the first subject enrolled to one week after the last subject completed the first dosing,assessed up to approximately 12 months

  3. For phase I:Maximum plasma concentration (Cmax) of Lutetium [Lu 177] Lu-XT033 in patients.

    Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. Cmax will be listed and summarized using descriptive statistics.

    Time frame: From the first subject enrolled to one week after the last subject completed the first dosing,assessed up to approximately 12 months

  4. For phase I:Time of observed drug concentration occurrence (Tmax) of Lutetium [Lu 177] Lu-XT033 in patients.

    Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. Tmax will be listed and summarized using descriptive statistics.

    Time frame: From the first subject enrolled to one week after the last subject completed the first dosing,assessed up to approximately 12 months

  5. For phase I:Area Under plasma concentration-time Curve from time 0 to 168 hours (AUC0-168) of Lutetium [Lu 177] Lu-XT033 in patients.

    Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. AUC0-168 will be listed and summarized using descriptive statistics.

    Time frame: From the first subject enrolled to one week after the last subject completed the first dosing,assessed up to approximately 12 months

  6. For phase II:Prostate-specific Antigen 50 (PSA50) Response

    PSA50 response was defined as the proportion of participants who had a \>= 50% decrease in PSA from baseline confirmed by a PSA measurement \>= 4 weeks later.

    Time frame: Through study completion, assessed up to 2 years.

Secondary outcomes

  1. For phase I:Prostate-specific Antigen 50 (PSA50) Response

    PSA50 response was defined as the proportion of participants who had a \>= 50% decrease in PSA from baseline confirmed by a PSA measurement \>= 4 weeks later.

    Time frame: Through study completion, assessed up to 2 years.

  2. For phase I/II:Best Percentage Change From Baseline in Prostate-specific Antigen (PSA) Level(PCWG3)

    Best percentage change from baseline in PSA level was defined as the maximum percent decrease at any time post-baseline.

    Time frame: Through study completion, assessed up to 2 years.

  3. For phase I/II:Time to PSA progression

    PSA progression was defined as: 1) Where a decline from baseline was documented, date that a \>= 25% increase in PSA and an absolute increase of 2 ng/mL or more from the nadir was documented and confirmed by a second consecutive value obtained at least 3 weeks later. Rises in PSA within the first 12 weeks of the date of first dose were ignored; 2) Where no decline from baseline was documented, PSA progression was defined as a \>= 25% increase from the baseline value along with an increase in absolute value of 2 ng/mL or more after 12 weeks from the date of first dose (without confirmation) as specified in the Prostate Cancer Clinical Trials Working Group 3 (PCWG3) guidelines.

    Time frame: Through study completion, assessed up to 2 years.

  4. For phase I/II:Radiographic Progression-free Survival (rPFS)

    Radiographic progression-free survival (rPFS) was defined as the time (in months) from the date of enrollment to the date of radiographic disease progression per the Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria or death due to any cause.

    Time frame: Through study completion, assessed up to 2 years.

  5. For phase I/II:Overall Response Rate (ORR)

    Overall Response Rate (ORR) was defined as the proportion of participants with Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR). ORR was based on RECIST 1.1 response for patients with measurable disease at baseline.

    Time frame: Through study completion, assessed up to 2 years.

  6. For phase I/II: Duration of Response (DOR)

    Duration of Response (DOR) was defined as the duration between the date of first documented Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) and the date of first documented radiographic progression or death due to any cause .

    Time frame: Through study completion, assessed up to 2 years.

  7. For phase I/II:Disease Control Rate (DCR)

    Disease control rate (DCR) was defined as the proportion of participants with Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) or Stable Disease (SD) according to RECIST v1.1.

    Time frame: Through study completion, assessed up to 2 years.

  8. For phase I/II:Health related quality of life(HRQOL)

    Patient evaluation with questionnaires regarding Quality of Life .

    Time frame: Through study completion, assessed up to 2 years.

  9. For phase I/II:Time to First Symptomatic Skeletal Event (SSE)

    Time to first Symptomatic Skeletal Event (SSE) was defined as the time (in months) from the date of enrollment to the date of the SSE or death from any cause. The SSE date was the date of first new symptomatic pathological bone fracture, spinal cord compression, tumor-related orthopedic surgical intervention, requirement for radiation therapy to relieve bone pain, or death due to any cause.

    Time frame: Through study completion, assessed up to 2 years.

  10. For phase I/II:Overall Survival (OS)

    Overall Survival (OS) was defined as the time (in months) from the date of enrollment to the date of death due to any cause. If the patient was not known to have died, then OS was censored. The censoring date was date of the last study visit, or contact, until the cut-off date.

    Time frame: Through study completion, assessed up to 2 years.

  11. For phase II:Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability])of [177Lu]Lu-XT033

    To evaluate the safety and tolerability of \[177Lu\]Lu-XT033 Injection assessed from the number and incidence of patients with adverse events using CTCAE v5.0 and physical examination, electrocardiogram and laboratory abnormality, etc

    Time frame: Through study completion, assessed up to 2 years.

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Dec 2027, 51 months after the start.

Of 96 industry-sponsored phase 1/2 interventional studies under Prostatic Neoplasms, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35. This study's planned 51 months is close to that.

Counting every sponsor, half of 210 studies reached it within 61 months; a quarter within 30 and three quarters within 85.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Dec 2025 → Dec 2027 and completion Dec 2025 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2023
First posted
Oct 13, 2023
StartActual
Sep 13, 2023
Primary completionEst.
Dec 31, 2027was Dec 2025
CompletionEst.
Dec 31, 2027was Dec 2025
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 2 sites removed
Show 2 added (2 China)
  • Peking University Cancer Hospital · Beijing, China
  • Fudan University Shanghai Cancer Center · Shanghai, China
Show 2 removed
  • Peking University Cancer Hospital · Beijing, China
  • Fudan University Shanghai Cancer Center · Shanghai, China
Nov 13, 2026
Primary completion
Dec 2025→Dec 31, 2027
Nov 13, 2026
Study completion
Dec 2025→Dec 31, 2027
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    2 sites added, 2 sites removed
    Show 2 added (2 China)
    • Peking University Cancer Hospital · Beijing, China
    • Fudan University Shanghai Cancer Center · Shanghai, China
    Show 2 removed
    • Peking University Cancer Hospital · Beijing, China
    • Fudan University Shanghai Cancer Center · Shanghai, China
    Primary completion Dec 2025→Dec 31, 2027
    Study completion Dec 2025→Dec 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06081686
Lead sponsor
Sinotau Pharmaceutical Group
Responsible party
Sponsor
First posted
Oct 13, 2023
Start date
Sep 13, 2023
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

Shan Zhang
Contact
zhangshan@sinotau.com
010-52805710
Dingwei Ye
principal investigator · Fudan University
Zhi Yang
principal investigator · Peking University Cancer Hospital & Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lutetium-177

Start the discussion